Upstate Active Clinical Trials

Study Title:

PERL Preventing Early Renal Loss in Diabetes: A multicenter clinical trial of allopurinol to prevent GFR loss in type 1 diabetes

What is the purpose of the study?

The purpose of this study is to find out whether a medication called allopurinol can prevent kidney problems, in particular the loss of kidney function, in people with type 1 diabetes.

Upstate Institutional Review Board (IRB) Number:

499866

Study/Protocol ID:

PERL

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

What is involved if I participate?

  • How long is the study?
    3.5 years
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Procedures during study visits include: physical exams, vital signs, blood collection, urinalysis, ECG, questionnaire completion.

Where will the study take place?

Clinical Research Unit at IHP (505 Irving Ave.)

ClinicalTrials.Gov ID:

NCT02017171

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu

Return to Previous Page || Search Again